Axelrad JE, Bazarbashi A, Zhou J, et al. - Given that exposure to hormone contraception was correlated with an increased risk of relapse of inflammatory bowel diseases (IBDs), researchers conducted this conducted a retrospective cohort study to analyze the impacts of cancer therapies, specifically hormone therapies, on the course of IBD. For this investigation, they collected data from five medical centers on IBD patients who received a subsequent diagnosis of breast or prostate cancer from 1997 through 2018. Study participants included 447 patients with IBD who had either breast or prostate cancer. Findings suggested an association of previous exposure to steroids, immunomodulators, or biologics with IBD relapse after a cancer diagnosis. IBD relapse was associated with hormone monotherapy and combination cytotoxic and hormone therapy. Investigators found that patients with IBD and breast or prostate cancer receiving hormone therapy have an increased risk for relapse of IBD and related adverse results.